Chivukula et al. (2021) utilized the mRNA therapeutic platform (MRT) to develop multivalent mRNA-LNP vaccine candidates containing unmodified mRNAs encoding full-length HA and NA antigens from several influenza strains which include both seasonal and pandemic influenza strains [112]. The gene discussed is XK; the disease is influenza.